AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04164810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.
Study NCT04164810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
Study NCT03929432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation with SLT
Description: Soterix Medical 1×1 transcranial Direct Current Stimulator for Clinical Trials (1x1 tDCS-CT).~Excitatory stimulation to the left hemisphere will be achieved through a 1x1 montage utilizing two carbon-rubber electrodes and 5x7 EASY pad sponges (A-tDCS \[excitatory\]left target; C-tDCS \[inhibitory\]right hemisphere). Each PWA will have a unique 5-digit tDCS program code for each treatment phase. One code will instruct the 1x1 tDCS-CT to administer active stimulation as describe above (i.e., 1.5 mA for 20 min). The other will administer 1.5 mA for only a few seconds to simulate active stimulation. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment
Study NCT03929432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation with SLT
Description: Control condition in which only SLT is administered.Participant receives 1.5 mA for only a few seconds to simulate active stimulation, then the stimulation will cease. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavanols-capsules
Description: Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-banana blend
Description: Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-high protein drink
Description: Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-berry blend
Description: Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-sports drink
Description: Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-peanut butter toast
Description: Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-oats
Description: Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-yogurt
Description: Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: II- Flavanol drink
Description: Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
Study NCT03526094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: II- Flavanol drink + banana blend
Description: Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
Study NCT03513913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI
Description: Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
Study NCT01651286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasal mask
Description: Using the nasal mask instead of the full face mask during the induction of general anesthesia
Study NCT01651286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasal mask
Description: Using the nasal mask instead of the full face mask during the induction of general anesthesia
Study NCT01651286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full face mask
Description: using a standard full face mask during the induction of general anesthesia.
Study NCT01651286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full face mask
Description: using a standard full face mask during the induction of general anesthesia.
Study NCT01128725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alzhamyd
Description: The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~* psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~* Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards.
Study NCT00001964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Cyclosporine A
Study NCT00001964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG
Study NCT00001964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: MMF
Study NCT04280991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise under mild normobaric hypoxia and normoxia
Description: The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
Study NCT04280991 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moderate intensity exercise under mild normobaric hypoxia and normoxia
Description: The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
Study NCT00915889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Either 6 or 8 telephone educational sessions
Study NCT00915889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: counseling and communications studies
Study NCT00915889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00915889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00915889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables
Description: Ancillary Studies
Study NCT00915889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: 6 weeks or 8 weeks of psychoeducational telephone sessions
Study NCT04114175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise BE
Description: Basic exercises related to amputation will be applied
Study NCT04114175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise BE+SS
Description: Basic exercises related to amputation + Spinal stabilization exercises will be applied
Study NCT00131352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Description: Single injection of 6 mL of hylan G-F 20 (Synvisc).
Study NCT00131352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline
Description: Single injection of 6 mL phosphate buffered saline.
Study NCT05238350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
Study NCT03683810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Lactoferrin in tablets 4g/daily
Study NCT03683810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin (rHuEPO, epoetin alfa)
Study NCT03683810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin (rHuEPO, epoetin alfa)
Study NCT03367169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimally invasive method
Description: type of surgical technique
Study NCT03367169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction method
Description: type of surgical technique
Study NCT05640362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural enzymes mouthwash
Description: Natural enzymes mouthwash contains numerous natural protein-enzymes, including lactoferrin, lysozyme, lactoperoxidase, glucose oxidase. These active ingredients were proposed to render this mouthwash to act as salivary substitutes by reinforcing the functions of available saliva, hence reinforcing the immune system in the oral cavity. It was expected to relieve the symptoms in xerostomia patients, and even more if the patients have salivary flow reduction by improving the functions of the limited amount of saliva. The potential mechanisms of action of the mouthwash to treat xerostomia may be related to: (1) lubrication effects to wet the oral mucosal surfaces; (2) antimicrobial properties that will reduce risks of mucosal irritation by infections; (3) absence of alcohol in the mouthwash Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
Study NCT05640362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Benzydamine mouthwash
Description: Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
Study NCT01899781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic-Cefamezin
Study NCT04475159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
Description: Pressurized Intraperitoneal Aerosol Chemotherapy will be delivered to the abdominal cavity by means of laparoscopy.
Study NCT00209144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Study NCT02287194 — intervention group
Intervention type: DEVICE
Intervention: SpyGlass
Description: The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
Study NCT03191942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified ortho-k lenses
Description: KETT MC lens
Study NCT03191942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ortho-k lenses
Description: KATT BeFree lens
Study NCT00658541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate 10 mg tablet
Description: 10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
Study NCT00658541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem Tartrate 10 mg tablet (Ambien®)
Description: 10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
Study NCT01598714 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Darco shoe
Description: Darco shoe
Study NCT01598714 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Podalux shoe
Description: Podalux shoe
Study NCT01598714 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard dressing shoe
Description: Standard dressing shoe
Study NCT01640015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
Study NCT01755936 — intervention group
Intervention type: OTHER
Intervention: Cardiac Magnetic Resonance Imaging
Description: For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
Study NCT01755936 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
Study NCT01125267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multifamily group-standard
Description: multifamily groups held twice a month focused on general problem solving method
Study NCT01220050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
Study NCT01220050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy for hyperparathyroidism for 26 weeks
Study NCT01408446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: Capsule 48mg three times a day after meals 8 weeks
Study NCT01408446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule 48mg three times a day after meals 8 weeks
Study NCT03483740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRGT
Description: Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
Study NCT03483740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV group therapy
Description: These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
Study NCT05745571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
Study NCT01798095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aplisol@ PPD material
Description: Determine equivalency of materials
Study NCT01798095 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aplisol@ PPD material
Description: Determine equivalency of materials
Study NCT01798095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reference Standard
Description: Reference standard material for comparison to newly produced materials.
Study NCT01798095 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference Standard
Description: Reference standard material for comparison to newly produced materials.
Study NCT03685981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentives mailer
Description: Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
Study NCT01324960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceplene®, IL-2, Azacitidine
Description: Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
Study NCT01324960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
Study NCT02063685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: R-CHOP or R-bendamustine
Description: As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days.
Study NCT02063685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP or R-bendamustine
Description: As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days.
Study NCT02063685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observation
Description: not maintenance therapy and followed-up with MRD monitoring.
Study NCT02063685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance weekly x4
Description: Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
Study NCT02063685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan + Maintenance
Description: single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
Study NCT02063685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Maintenance
Description: Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
Study NCT01735383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Tablets USP 500mg
Description: 500 mg tablet once a day
Study NCT01735383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Tablets USP 500 mg
Description: 500 mg tablet once a day
Study NCT03183752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg metformin three times daily
Study NCT03183752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg placebo three times daily
Study NCT01531582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
Study NCT03947268 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
Study NCT01354522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Doxorubicin, Cyclophosphamide
Description: docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
Study NCT01354522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cyclophosphamide, Capecitabine
Description: docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles